Given the dual biological functions of TNF-α in arthritis mediated by TNFRI and TNFRII, and potential technical difficulties depleting EV-carried TNF-α in vivo, neutralizing TNF-α with biologics may not be an ideal therapeutic approach for treating OA. This evidence concerns the gene TNFRSF1B and arthritic joint disease.